Published in Med Oncol on June 01, 2017
Androgen deprivation therapy for prostate cancer. JAMA (2005) 6.07
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst (2009) 4.87
Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol (2009) 4.07
Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol (2013) 3.74
The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev (2005) 3.11
Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol (2003) 3.10
Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol (2006) 3.09
Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol (2009) 2.96
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol (2008) 2.68
Androgen deprivation therapy and cardiovascular risk. J Clin Oncol (2011) 2.55
Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2015) 2.52
Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol (2006) 2.46
Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) (2003) 2.07
Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) (2005) 1.90
Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology (2003) 1.74
Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol (2003) 1.71
Early development of the metabolic syndrome after chemotherapy for testicular cancer. Ann Oncol (2012) 1.70
American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients--2002 update. Endocr Pract (2004) 1.69
A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int (2011) 1.65
Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors. Br J Cancer (2013) 1.60
The quality of life and hormonal disturbances in testicular cancer survivors in Cisplatin era. Eur Urol (2007) 1.57
Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology (2008) 1.53
Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) (2010) 1.46
Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. J Clin Oncol (2016) 1.45
Androgen deficiency symptoms in testicular cancer survivors are associated with sexual problems but not with serum testosterone or therapy. Urology (2009) 1.41
Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol (2006) 1.39
Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med (2006) 1.38
Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer. J Clin Oncol (2010) 1.34
Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male (2003) 1.33
Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab (2006) 1.30
Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol (1997) 1.29
Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology (2007) 1.29
Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer (2004) 1.25
Global incidence and outcome of testicular cancer. Clin Epidemiol (2013) 1.22
Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol (2008) 1.21
Oligozoospermia with normal fertility in male mice lacking the androgen receptor in testis peritubular myoid cells. Proc Natl Acad Sci U S A (2006) 1.21
Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer (2005) 1.15
Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol (1999) 1.15
Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis (2011) 1.14
Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Support Care Cancer (2014) 1.10
Thinking with your gonads: testosterone and cognition. Trends Cogn Sci (2006) 1.07
Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol (2011) 1.03
The blood in systemic disorders. Lancet (2000) 1.00
Clinical exercise interventions in prostate cancer patients--a systematic review of randomized controlled trials. Support Care Cancer (2011) 0.99
Androgen deprivation therapy for prostate cancer: recommendations to improve patient and partner quality of life. J Sex Med (2010) 0.98
Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis. PLoS One (2015) 0.95
Hypogonadism in male patients with cancer. Cancer (2006) 0.95
The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer (2001) 0.95
Testicular function after cytotoxic chemotherapy: evidence of Leydig cell insufficiency. J Clin Oncol (1999) 0.94
Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med (2010) 0.93
Endocrinological late effects after chemotherapy for testicular cancer. Br J Cancer (1996) 0.93
Low testosterone levels and increased inflammatory markers in patients with cancer and relationship with cachexia. J Clin Endocrinol Metab (2012) 0.90
The pituitary-Leydig cell axis before and after orchiectomy in patients with stage I testicular cancer. Eur J Cancer (2011) 0.90
Population-based study of cardiovascular mortality among patients with prostate cancer treated with radical external beam radiation therapy with and without adjuvant androgen deprivation therapy at the British Columbia Cancer Agency. Int J Radiat Oncol Biol Phys (2010) 0.89
Long-term toxicity of chemotherapy for testicular cancer--the cost of cure. Br J Cancer (1990) 0.89
Managing hot flushes in men after prostate cancer--a systematic review. Maturitas (2009) 0.89
Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB. J Support Oncol (2010) 0.87
Adipokines in patients with cancer anorexia and cachexia. J Investig Med (2010) 0.87
High-dose anabolic androgenic steroids modulate concentrations of nerve growth factor and expression of its low affinity receptor (p75-NGFr) in male rat brain. J Neurosci Res (1997) 0.86
Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. Eur J Cancer (2015) 0.86
Performance of total testosterone measurement to predict free testosterone for the biochemical evaluation of male hypogonadism. J Urol (2012) 0.86
A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab (2015) 0.84
Association between hypogonadism, symptom burden, and survival in male patients with advanced cancer. Cancer (2014) 0.84
How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients? Can J Urol (2005) 0.84
Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial. Support Care Cancer (2013) 0.83
Management of complications of androgen deprivation therapy in the older man. Crit Rev Oncol Hematol (2008) 0.83
Changes in cerebral glucose metabolism and visuospatial capability in hypogonadal males under testosterone substitution therapy. Exp Clin Endocrinol Diabetes (2001) 0.82
Risk factors for post-treatment hypogonadism in testicular cancer patients. Eur J Endocrinol (2008) 0.82
Androgen deprivation therapy through bilateral orchiectomy: increased metabolic risks. Asian J Androl (2011) 0.82
The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study. J Sex Med (2010) 0.82
Cancer-related symptoms predict psychological wellbeing among prostate cancer survivors: results from the PiCTure study. Psychooncology (2015) 0.82
Plasma testosterone and luteinizing hormone levels during levo-alpha-acetylmethadol maintenance and withdrawal. Clin Pharmacol Ther (1984) 0.81
Testosterone deficiency in testicular germ-cell cancer patients is not influenced by oncological treatment. Int J Androl (2010) 0.80
The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada. J Oncol (2015) 0.79
Damage of hormonal function and bone metabolism in long-term survivors of testicular cancer. Neoplasma (2009) 0.79
Testicular function following combination chemotherapy with cis-platin, vinblastine, and bleomycin. Med Pediatr Oncol (1984) 0.79
Presence of delta opioid receptors on a subset of hypothalamic gonadotropin releasing hormone (GnRH) neurons. Brain Res (2006) 0.78
Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis. Prostate Cancer Prostatic Dis (2014) 0.78
Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer. Support Care Cancer (2010) 0.78
Does pharmacological castration as adjuvant therapy for prostate cancer after radiotherapy affect anxiety and depression levels, cognitive functions and quality of life? Psychooncology (2011) 0.77
Testosterone Therapy Among Prostate Cancer Survivors. Sex Med Rev (2016) 0.77
Impact of Androgen Deprivation Therapy on Sexual and Hormonal Function in Patients Receiving Radiation Therapy for Prostate Cancer. Isr Med Assoc J (2016) 0.77
Course and Moderators of Hot Flash Interference during Androgen Deprivation Therapy for Prostate Cancer: A Matched Comparison. J Urol (2015) 0.77
Clinical Predictors of Fatigue in Men With Non-Metastatic Prostate Cancer Receiving External Beam Radiation Therapy. Clin J Oncol Nurs (2015) 0.76
Emotional disorders in testicular cancer survivors in relation to hypogonadism, androgen receptor polymorphism and treatment modality. J Affect Disord (2009) 0.76
Testosterone deficiency and quality of life in Australasian testicular cancer survivors: a prospective cohort study. Intern Med J (2014) 0.75
Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Support Care Cancer (2016) 0.75
Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy. Can Urol Assoc J (2016) 0.75